Advertisement
In addition, Grant Thornton LLP was ratified as the Company's independentaccountants for the year 2008.
Claire Kruger told the shareholders that Spherix management is focused andwill continue to focus on the path forward necessary to bring Naturlose tomarket as a drug to treat Type 2 diabetes. To this end, three crucialactivities are being undertaken in parallel:
Advertisement
At a Board of Directors meeting later the same day, the following slate ofCorporate Officers was elected:
Certain statements contained herein are "forward looking" statements asdefined in the Private Securities Litigation Reform Act of 1995. Because suchstatements include risks and uncertainties, actual results may differmaterially from those expressed or implied. Factors that could cause actualresults to differ materially from those expressed or implied include, but arenot limited to, those discussed in filings by the Company with the Securitiesand Exchange Commission, including the filing on Form 8-K made on October 10,2007.
Spherix's mission is to create value and increase shareholder wealththrough innovations that benefit our clients and the human condition. Spherixoffers innovations in biotechnology, and provides technical and regulatoryconsulting services to biotechnology and pharmaceutical companies.
Spherix's Internet address is http://www.spherix.com.-- Douglas T. Brown, Senior VP and Manager of Corporate Banking Government Contracting, PNC Bank -- A. Paul Cox, Jr., Principal, Asset Protection Company -- Claire L. Kruger, Chief Executive Officer and Chief Operating Officer, Spherix -- Gilbert V. Levin, Ph.D., Director of Science and Technology, Spherix -- Robert A. Lodder, Jr., President, Spherix; and Professor, College of Pharmacy, University of Kentucky -- Aris Melissaratos, Senior Advisor to the President of Johns Hopkins University -- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods International
SOURCE Spherix Incorporated
